Physician

James Michael Flynn, M.D.

According to 2025 Medicare claims, James Flynn, M.D. (NPI: 1174584361) practices cardiology in the Manchester-Nashua, NH market, with the plurality of this provider's patient population coming from Hillsborough, NH. This provider's primary affiliated billing organization is CARDIOVASCULAR SPECIALISTS OF NEW ENGLAND, LLC (NPI: 1992563589; TIN: 991635988) and primary practice location at 03053-3417. Flynn is affiliated with the Aledade 205 New England MSSP Enhanced (ACO ID: A5370), Aledade 201 National MSSP (ACO ID: A5522), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Flynn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 748 traditional Medicare patients, billed 1,829 HCPCS/CPT codes, and received $251,552 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,379 prescription claims across 288 beneficiaries totaling $279,895 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 27 records totaling $22,190. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $76,677 to $279,895. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	873	1,707	$164,313
2016	916	1,713	$178,644
2017	965	1,634	$189,813
2018	799	1,354	$160,144
2019	663	1,166	$154,978
2020	631	1,048	$130,785
2021	560	889	$133,690
2022	639	1,025	$148,382
2023	491	869	$103,233
2024	748	1,829	$251,552

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	220	1,415	$76,677
2016	217	1,374	$79,860
2017	238	1,345	$99,659
2018	214	1,224	$113,890
2019	231	1,361	$108,465
2020	255	1,585	$146,680
2021	215	1,257	$169,115
2022	214	1,205	$203,567
2023	208	1,209	$246,579
2024	288	1,379	$279,895

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	95	95	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	242	300	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	134	142	$57
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	112	114	$11
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	144	159	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	106	7,750	$149,028
Farxiga	Dapagliflozin Propanediol	43	2,520	$46,262
Xarelto	Rivaroxaban	38	1,920	$34,320
Jardiance	Empagliflozin	12	840	$16,378
Crestor	Rosuvastatin Calcium	12	360	$3,266

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$1,190	Inari Medical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$21,000	Abbott Laboratories
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Michael Flynn, M.D.?

Tedicare shows public-source Medicare data for James Michael Flynn, M.D. (NPI 1174584361), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Michael Flynn, M.D. have ACO affiliation data?

James Michael Flynn, M.D. is shown with ACO affiliation data for Aledade 205 New England MSSP Enhanced (MSSP, ACO ID A5370), Aledade 201 National MSSP (MSSP, ACO ID A5522), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to James Michael Flynn, M.D.?

James Michael Flynn, M.D. is linked to CARDIOVASCULAR SPECIALISTS OF NEW ENGLAND, LLC (billing NPI 1992563589) in the available physician profile data.

Does James Michael Flynn, M.D. have Open Payments data?

James Michael Flynn, M.D. has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.